Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.89 |
| ▸ | HPGD | P15428 | 3/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.89 |
| ▸ | HTR2C | P28335 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | HTR1A | P08908 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | DRD2 | P14416 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | DRD4 | P21917 | 1/20 | 0.89 |
| ▸ | HTR1D | P28221 | 1/20 | 0.89 |
| ▸ | HTR1B | P28222 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketanserin SCHEMBL34294 | 0.94 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL4862503 | 0.94 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL29361038 | 0.94 | HTR2A (1.00) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL30028921 | 0.93 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL2030457 | 0.93 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL1532014 | 0.93 | HTR2A (0.98) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Ketanserin SCHEMBL5614705 | 0.91 | HTR2A (0.94) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| Hydrochloric Acid SCHEMBL9870098 | 0.90 | HTR2A (0.91) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| SCHEMBL25837175 | 0.89 | HTR2A (0.89) | HTR2ACYP3A4HPGDCYP1A2HTR2C | |
| SCHEMBL11015897 | 0.89 | HTR2A (0.89) | HTR2ACYP3A4HPGDCYP1A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023081403-A1 | ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101677971-A | The combination of 5-HT2A inverse agonist and antagonist and antipsychotic drug | ACADIA PHARM INC | 2010-03-24 | — | — | CN | claimed |
| EP-2134330-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | Acadia Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2008116024-A2 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARMACEUTICALS INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2A 37/4885CYP3A4 242/4885HPGD 1831/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR2A 2/4885CYP3A4 2453/4885HPGD 1973/4885 |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | HTR2A 671/4885CYP3A4 4561/4885HPGD 2254/4885 |
| US-20090053329-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | HTR2A 1/4885CYP3A4 809/4885HPGD 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.